Janus Henderson US Venture A2 HEUR |
Performance History | 30/09/2024 |
Growth of 1,000 (EUR) |
Fund | 28.3 | 3.0 | -28.5 | 11.0 | 10.7 | |
+/-Cat | - | - | - | - | - | |
+/-Idx | - | - | - | - | - | |
Category: Other Equity | ||||||
Benchmarks: - |
Key Stats | ||
NAV 31/10/2024 | EUR 33.47 | |
Day Change | -1.24% | |
Morningstar Category™ | Other Equity | |
ISIN | IE0009534169 | |
Fund Size (Mil) 31/10/2024 | USD 94.54 | |
Share Class Size (Mil) 31/10/2024 | EUR 7.16 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 07/08/2024 | 2.47% |
Investment Objective: Janus Henderson US Venture A2 HEUR |
The Fund’s investment objective is capital appreciation. It pursues its objective by investing at least 80% of its net assets in equities (also known as company shares) of US Companies. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Scott Stutzman 01/07/2016 | ||
Aaron Schaechterle 01/09/2023 | ||
Click here to see others | ||
Inception Date 31/12/1999 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
Russell 2000 Growth TR USD | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Janus Henderson US Venture A2 HEUR | 30/09/2024 |
|
|
Top 5 Holdings | Sector | % |
Stride Inc | Consumer Defensive | 2.26 |
SS&C Technologies Holdings Inc | Technology | 2.15 |
Vaxcyte Inc Ordinary Shares | Healthcare | 1.99 |
The Descartes Systems Group Inc | Technology | 1.77 |
Blackbaud Inc | Technology | 1.71 |
Increase Decrease New since last portfolio | ||
Janus Henderson US Venture A2 HEUR |